The following 5 biotech companies have strong catalysts and/or strong chart signals that indicate a trade to the long side could be in order. With the current choppy markets, opportunities for long trades are few and far between. I will…
Amicus Therapeutics Should See a Big Upside Move On Positive Phase 3 Data
One company that has really received a ton of attention lately has been Sarepta Therapeutics (SRPT). Only a few weeks ago, the stock was trading in the $3 to $4 range. On 10/3/12, the company announced that it received positive…
Quantitative Easing: Fractioning The Dollar, Undervaluing The Markets
On a regular basis, I hear guests on CNBC constantly saying the market is overbought. After awhile, I wonder if these individuals learned about modern finance from a Cracker-Jack box. These same people were screaming at the world in 2008…
Speculation In The Patent Litigation Segment: Seeking Out The Next Big Stock Movers.
There has been a lot of buzz lately about Vringo’s (VRNG) patent infringement lawsuit against Google (GOOG). Google’s ad placement system and its possible infringement of the Lang/Kosak Relevancy Filtering Technology with patents 420 and 664 are being called into…
A Message To VOCE Capital And Obagi Shareholders: Take Action Or Get Off The Pot
Excerpt: I chose the title to this article based on the old adage of “sh**t or get off the pot” — my sentiments regarding the ongoing Obagi Medical Products (OMPI) saga that has escalated to its current point after VOCE…
NUPATHE (PATH) Due Dilligence
Alert: I bought $PATH. Will write about it tomorrow NuPathe (PATH) is my next catalyst pick, I believe we could see a 50% move or more in the stock price to the upside by Jan. 17th. I have also noticed…
Answering critics: knowing the difference between good DD and “pump and dump.”
In the stock world, the term “pump and dump” is overused and misunderstood, and I get accused of engaging in such activity.quite a bit and quite frankly, it pisses me off. What exactly is pump and dump? According to Wikipedia:…
Amicus Therapeutics Could See A Move Like Sarepta On Positive Phase 3 Data
One company that has really received a ton of attention lately has been Sarepta Therapeutics (SRPT). Only a few weeks ago, the stock was trading in the $3 to $4 range. On 10/3/12, the company announced that it received positive…
Savient Pharmaceuticals May Continue To Run Higher
Savient Pharmaceuticals (SVNT) enjoyed a blistering third quarter, as shareholders racked up an impressive 363% gain, making it the largest Q3 gainer in ahead of other companies such as Sarepta Therapeutics (SRPT) 313%, Hemispherx Biopharma (HEB) 188%, Catalyst Pharmaceutical Partners…
